[关键词]
[摘要]
目的 探讨速感宁胶囊联合磷酸奥司他韦对流行性感冒患者血清炎性因子及免疫功能的影响。方法 回顾性分析2020年2月—2021年2月在天津市宁河区医院诊治的96例流行性感冒患者临床资料,根据用药的差别分为对照组和治疗组,每组各48例。对照组口服磷酸奥司他韦胶囊,75 mg/次,2次/d;治疗组在对照组基础上口服速感宁胶囊,0.9 g/次,3次/d。两组患者均经5 d治疗。观察两组患者临床疗效,比较治疗前后两组患者临床症状消失时间,及血清超敏C反应蛋白(hs-CRP)、降钙素原(PCT)、白细胞介素-17(IL-17)、单核细胞趋化蛋白-1(MCP-1)和巨噬细胞移动抑制因子(MIF)水平。结果 经治疗,对照组有效率为83.33%,显著低于治疗组的97.92%(P<0.05)。经治疗,治疗组临床症状改善时间明显早于对照组(P<0.05)。经治疗,两组患者血清hs-CRP、PCT、IL-17、MCP-1、MIF水平均明显降低,且治疗组降低更明显(P<0.05)。结论 速感宁胶囊联合磷酸奥司他韦胶囊治疗流行性感冒患者可显著改善临床症状,降低机体炎症介质表达,具有一定的临床推广应用价值。
[Key word]
[Abstract]
Objective To investigate the efficacy of Suganning Capsules combined with oseltamivir phosphate in treatment of influenza and its effect on serum inflammatory factors. Methods The clinical data of 96 patients with influenza Patients in Tianjin Ninghe District Hospital from February 2020 to February 2021 were analyzed retrospectively and divided into control and treatment groups, and each group had 48 cases. Patients in the control group were po administered with Oseltamivir Phosphate Capsules, 75 mg/time, twice daily. Patients in the treatment group were po administered with Suganning Capsules, 0.9 g/time, three times daily. Patients in two groups were treated for 5 d. After treatment, the clinical efficacy was evaluated, the disappearance time of clinical symptoms, and the serological indexes of hs-CRP, PCT, IL-17, MCP-1 and MIF in two groups before and after treatment were compared. Results After treatment, the effective rate in the control group was 83.33%, which was significantly lower than 97.92% in the treatment group (P < 0.05). After treatment, the improvement time of clinical symptoms in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the serum levels of hs-CRP, PCT, IL-17, MCP-1 and MIF were significantly decreased in two groups, especially in the treatment group (P < 0.05). Conclusion Suganning Capsules combined with oseltamivir phosphate in treatment of influenza can significantly improve clinical symptoms and reduce the expression of inflammatory mediators, which has a certain clinical application value.
[中图分类号]
R974
[基金项目]
天津市卫生和计划委员会课题(2015RB15401)